Morgan Stanley lowered the firm’s price target on Align Technology (ALGN) to $280 from $310 and keeps an Overweight rating on the shares. Shares “may ebb on disappointing volume” and Q4 targets that were below the firm’s and Street’s view amid a continuing sluggish demand backdrop, but expectations were low and the company is stepping up the buyback and pointing to margin improvement in 2025, while “addressing areas under its control,” the analyst tells investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- Align Technology price target lowered to $275 from $285 at Stifel
- Align Technology price target lowered to $275 from $285 at Piper Sandler
- Align Technology price target lowered to $276 from $325 at Baird
- Align Technology sees Q4 revenue $995M-$1.015B, consensus $1.01B
- Align Technology introduces Invisalign Smile Architect